FGFR2 and breast carcinoma: FGFR2 amplification, which occurred in 26 (1.4%) and 15 (1.5%) breast cancer patients in the METABRIC and TCGA datasets, respectively, was observed in all subtypes except the claudin-low subtype (Fig. 5a, Additional file 4: Fig. S8a).